Next Article in Journal
A Systematic Literature Review for Evidence of Aphanizomenon flos-aquae Toxigenicity in Recreational Waters and Toxicity of Dietary Supplements: 2000–2017
Next Article in Special Issue
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
Previous Article in Journal
Staphylococcus aureus Toxins and Their Molecular Activity in Infectious Diseases
Previous Article in Special Issue
Detection of Clostridium tetani Neurotoxins Inhibited In Vivo by Botulinum Antitoxin B: Potential for Misleading Mouse Test Results in Food Controls
Article

Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study

1
Centre for Neurodiagnostic and Therapeutic Services (CNS), Metropolitan Medical Centre, Manila 1012, Philippines
2
Department of Neurology & Psychiatry, Faculty of Medicine and Surgery, University of Santo Tomas, Manila 1008, Philippines
3
Ipsen Group, Boulogne-Billancourt, 92100 Paris, France
4
Division of Neurology, Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur 59100, Malaysia
5
Department of Rehabilitation Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
6
Department of Rehabilitation Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
7
Department of Rehabilitation Medicine, Tan Tock Seng Hospital, Novena 308433, Singapore
*
Author to whom correspondence should be addressed.
Toxins 2018, 10(7), 253; https://doi.org/10.3390/toxins10070253
Received: 29 May 2018 / Revised: 11 June 2018 / Accepted: 11 June 2018 / Published: 21 June 2018
The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms. ONTIME (NCT02321436) was a 28-week, exploratory, double-blind, randomized, placebo-controlled study of abobotulinumtoxinA 500U in patients with ULS (Modified Ashworth Scale [MAS] score ≥ 2) 2–12 weeks post-stroke. Patients were either symptomatic or asymptomatic (only increased MAS) at baseline. Primary efficacy outcome measure: time between injection and visit at which re-injection criteria were met (MAS ≥ 2 and ≥1, sign of symptomatic spasticity: pain, involuntary movements, impaired active or passive function). Forty-two patients were randomized (abobotulinumtoxinA 500U: n = 28; placebo: n = 14) with median 5.86 weeks since stroke. Median time to reach re-injection criteria was significantly longer for abobotulinumtoxinA (156 days) than placebo (32 days; log-rank: p = 0.0176; Wilcoxon: p = 0.0480). Eleven (39.3%) patients receiving abobotulinumtoxinA did not require re-injection for ≥28 weeks versus two (14.3%) in placebo group. In this exploratory study, early abobotulinumtoxinA treatment significantly delayed time to reach re-injection criteria compared with placebo in patients with post-stroke ULS. These findings suggest an optimal time for post-stroke spasticity management and help determine the design and sample sizes for larger confirmatory studies. View Full-Text
Keywords: abobotulinumtoxinA; botulinum toxin type A; upper limb spasticity; post-stroke; early use; ONTIME abobotulinumtoxinA; botulinum toxin type A; upper limb spasticity; post-stroke; early use; ONTIME
Show Figures

Figure 1

MDPI and ACS Style

Rosales, R.L.; Balcaitiene, J.; Berard, H.; Maisonobe, P.; Goh, K.J.; Kumthornthip, W.; Mazlan, M.; Latif, L.A.; Delos Santos, M.M.D.; Chotiyarnwong, C.; Tanvijit, P.; Nuez, O.; Kong, K.H. Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins 2018, 10, 253. https://doi.org/10.3390/toxins10070253

AMA Style

Rosales RL, Balcaitiene J, Berard H, Maisonobe P, Goh KJ, Kumthornthip W, Mazlan M, Latif LA, Delos Santos MMD, Chotiyarnwong C, Tanvijit P, Nuez O, Kong KH. Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins. 2018; 10(7):253. https://doi.org/10.3390/toxins10070253

Chicago/Turabian Style

Rosales, Raymond L., Jovita Balcaitiene, Hugues Berard, Pascal Maisonobe, Khean J. Goh, Witsanu Kumthornthip, Mazlina Mazlan, Lydia A. Latif, Mary M.D. Delos Santos, Chayaporn Chotiyarnwong, Phakamas Tanvijit, Odessa Nuez, and Keng H. Kong 2018. "Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study" Toxins 10, no. 7: 253. https://doi.org/10.3390/toxins10070253

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop